A federal securities class action has been filed against VistaGen Therapeutics Inc., alleging that the company and its executives made false or misleading statements regarding the likelihood of success in its fasedienol clinical trials. The complaint claims that VistaGen promoted the PALISADE-3 Phase 3 trial as likely to succeed based on prior positive results and operational improvements, while concealing material adverse facts. Following the disclosure, VistaGen's stock price dropped over 81 percent to open at $0.88 per share. Investors who purchased VistaGen securities between April 1, 2024 and December 16, 2025 may seek to serve as lead plaintiff in the case, with a deadline to do so set for March 16, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602140749PRIMZONEFULLFEED9654166) on February 14, 2026, and is solely responsible for the information contained therein.